Literature DB >> 3012111

Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity.

R D Schrier, M B Oldstone.   

Abstract

Peripheral blood mononuclear cells harvested from healthy adults seropositive for human cytomegalovirus (HCMV) and cultured with laboratory strain AD-169 demonstrated human leukocyte antigen-restricted and HCMV-specific killing on target cells infected with either HCMV laboratory strain AD-169 or recent low-passage HCMV isolates. These results indicated that the determinants recognized by cytotoxic T lymphocytes (CTLs) are shared among different strains of HCMV. However, when low-passage isolates, rather than high-passage AD-169 virions, were used to stimulate CTL activity, the lytic response was significantly lower against all targets. Mixing of AD-169 and low-passage HCMV isolates induced low CTL activity. Collectively, the findings suggest that low-passage HCMV isolates have dual effects--antigenic stimulation and immunosuppression--whereas laboratory strain AD-169 is primarily immunogenic. The study of several recent isolates indicated that they varied in their ratio of immunostimulation to suppression, that infectious virus was necessary to produce suppression, and that suppressive isolates did not have to be present at the initiation of culture to exert their suppressive effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012111      PMCID: PMC253047     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Diseases and mechanisms of persistent DNA virus infection: latency and cellular transformation.

Authors:  J S Pagano
Journal:  J Infect Dis       Date:  1975-08       Impact factor: 5.226

2.  Analysis of cytomegalovirus genomes with restriction endonucleases Hin D III and EcoR-1.

Authors:  B A Kilpatrick; E S Huang; J S Pagano
Journal:  J Virol       Date:  1976-06       Impact factor: 5.103

Review 3.  The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1971-07-22       Impact factor: 91.245

4.  Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery.

Authors:  D P Stevens; L F Barker; A S Ketcham; H M Meyer
Journal:  JAMA       Date:  1970-02-23       Impact factor: 56.272

5.  Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions.

Authors:  W P Carney; M S Hirsch
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

6.  Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis.

Authors:  W P Carney; V Iacoviello; M S Hirsch
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

7.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

8.  Mechanisms of immunosuppression in cytomegaloviral mononucleosis.

Authors:  C R Rinaldo; W P Carney; B S Richter; P H Black; M S Hirsch
Journal:  J Infect Dis       Date:  1980-04       Impact factor: 5.226

9.  Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection.

Authors:  R D Schrier; J A Nelson; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

Review 10.  Latent infection and the elusive cytomegalovirus.

Authors:  M C Jordan
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  13 in total

1.  Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus.

Authors:  S Bandyopadhyay; S H Oh; S Michelson; D S Miller; J L Virelizier; S E Starr
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

2.  Perturbation of differentiated functions during viral infection in vivo. In vivo relationship of host genes and lymphocytic choriomeningitis virus to growth hormone deficiency.

Authors:  A Tishon; M B Oldstone
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

3.  Rous-Whipple Award Lecture. Viruses and diseases of the twenty-first century.

Authors:  M B Oldstone
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

Review 4.  Acquisition of cytomegalovirus infection: an update.

Authors:  B A Forbes
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

5.  Inhibition of T-lymphocyte mitogenic responses and effects on cell functions by bovine herpesvirus 1.

Authors:  J J Carter; A D Weinberg; A Pollard; R Reeves; J A Magnuson; N S Magnuson
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Suppression of monocyte functions by human cytomegalovirus.

Authors:  N A Buchmeier; N R Cooper
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

7.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Priming of immature thymocytes to CD3-mediated apoptosis by infection with murine cytomegalovirus.

Authors:  Y Koga; K Tanaka; Y Y Lu; M Oh-Tsu; M Sasaki; G Kimura; K Nomoto
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Human cytomegalovirus productively infects primary differentiated macrophages.

Authors:  C E Ibanez; R Schrier; P Ghazal; C Wiley; J A Nelson
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence.

Authors:  H W Roenhorst; C G Kallenberg; T H The
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.